| Date | Form | Description | Docs | XBRL | Pages |
| 09/27/10 | DEF 14A | Definitive proxy statements |
|
21 | |
| 09/14/10 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
58 | |
| 09/14/10 | 10-Q/A | Quarterly report pursuant to sections 13 or 15(d) |
|
14 | |
| 08/24/10 | 3 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 08/20/10 | 8-K | Current report filing |
|
3 | |
| 07/27/10 | CT ORDER | Confidential treatment order |
|
1 | |
| 07/27/10 | UPLOAD | SEC-generated letter |
|
1 | |
| 07/21/10 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
11 | |
| 07/20/10 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
32 | |
| 07/20/10 | 8-K | Current report filing |
|
41 |
Latest News & Events
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Read More...Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Read More...Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
Read More...